雷珠单抗玻璃体内注射联合光凝治疗早产儿视网膜病变的效果

Efficacy of intravitreal injection of ranibizumab combined with laser photocoagulation in the treatment of retinopathy of prematurity

目的评价雷珠单抗玻璃体内注射联合光凝治疗早产儿视网膜病变的临床疗效。方法回顾性分析2014年10月至2017年12月早产儿视网膜病变30例(60眼)的资料。所有患者均接受雷珠单抗玻璃体内注射治疗。对治疗后附加病变再次出现、烤及暗上新生血管不完全消退者进行激光光凝治疗。观察临床疗效及并发症。结果经雷珠单抗玻璃体内注射治疗后,随访6周,38眼(63.3%)病变完全消退,新生血管及出血吸收,病变瘢痕化或血管继续发育至锯齿缘。有22眼(36.7%)复发,包括阈值期4眼,阈值前期4眼,急进型14眼,均进行激光光凝治疗后病变完全消退,再次随访6周,病情稳定,未复发。本组患儿均未发生治疗相关并发症。结论联合视网膜激光光凝对雷珠单抗玻璃体内注射治疗后复发的早产儿视网膜病变可获得满意疗效。

Objective To evaluate the clinical efficacy of intravitreal injection of ranibizumab combined with laser photocoagulation on the treatment of retinopathy of prematurity. Methods The data of 60 eyes of 30 cases with retinopathy of prematurity from Oct. 2014 to Dec. 2017 were analyzed retrospectively. All cases were treated with intravitreal injection of ranibizumab. Laser photocoagulation was treated for complications and neovascularization on the ridge. The clinical efficacy and complications were observed. Results Followed up for 6 weeks after intravitreal injection of ranibizumab, the lesions completely disappeared in 38 eyes ( 63. 3%) with neovascular and hemorrhagic absorption, and vascular development to serrate or scar lesions. Twenty-two eyes ( 36. 7%) recurred, included 4 eyes of threshold stage ,4 eyes of pre-threshold, and 14 eyes of aggressive posterior. The lesions of 11 cases completely disappeared after laser photocoagulation. The condition was stable and no complication occurred after treatment. No treatment related adverse reactions was found in 30 cases. Conclusion The intravitreal injection of ranibizumab combined with laser photocoagulation for retinopathy of prematurity is effective.